|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Patient | Type | Stage | TNM | IHC FAS (cyt) | IHC FAS (mem) | IHC P53 (nuc) | IHC P53 (cyt) | *FAS* exon 9 | *TP53* exons 5-8 | s*FAS* |
| 1 | CPTC | I | T1N0M0 | NA | NA | NA | NA | NL | NL | NA |
| 2 | CPTC | I | T2N0M0 | 2 | 2 | NA | NA | NL | NL | 3 |
| 3 | CPTC | I | T2N0M0 | 0 | 0 | NA | NA | NL | NL | NA |
| 4 | CPTC | I | T1N1aM0 | 3 | 3 | 0 | 0 | NL | NL | NA |
| 5 | CPTC | I | T1N0M0 | 2 | 2 | 0 | 0 | NL | NL | NA |
| 6 | CPTC | I | T2N0M0 | 2 | 1 | NA | NA | NL | NL | 4 |
| 7 | CPTC | I | T1N0M0 | 1 | 2 | NA | NA | NL | NL | NA |
| 8 | CPTC | I | T1N0M0 | 3 | 3 | NA | NA | NL | NL | NA |
| 9 | CPTC | I | T1N0M0 | 2 | 2 | 0 | 0 | NL | NL | NA |
| 10 | CPTC | I | T2N0M0 | 1 | 1 | 0 | 0 | NL | NL | 6 |
| 11 | CPTC | I | TxN0M0 | NA | NA | 0 | 0 | NL | NL | NA |
| 12 | CPTC | I | TxN0M0 | 3 | 3 | 0 | 1 | NL | NL | NA |
| 13 | CPTC | I | T2N0M0 | 3 | 3 | 0 | 0 | NL | NL | 7 |
| 14 | CPTC | I | T1N0M0 | 2 | 2 | 0 | 0 | NL | NL | 10 |
| 15 | CPTC | I | T2N1aM0 | 1 | 2 | 0 | 0 | NL | NL | NA |
| 16 | CPTC | I | T1N0M0 | 1 | 1 | 0 | 0 | NL | NL | NA |
| 17 | CPTC | II | T1N1aM0 | 0 | 3 | 0 | 0 | NL | NL | NA |
| 18 | CPTC | II | T2N0M0 | NA | NA | NA | NA | NL | NL | NA |
| 19 | CPTC | II | T2N0M0 | NA | NA | NA | NA | NL | NL | NA |
| 20 | CPTC | II | T2N1aM0 | NA | NA | NA | NA | NL | NL | NA |
| 21 | CPTC | II | T2N0M0 | NA | NA | 0 | 0 | NL | NL | 8 |
| 22 | CPTC | II | T2N0M0 | 3 | 3 | 0 | 0 | NL | NL | NA |
| 23 | CPTC | II | T2N0M0 | 3 | 3 | 0 | 0 | NL | NL | 9 |
| 24 | CPTC | II | T2N0M0 | 2 | 0 | 0 | 0 | NL | NL | 5 |
| 25 | CPTC | II | T2N0M0 | 2 | 2 | 0 | 1 | NL | NL | 12 |
| 26 | CPTC | II | T2N0M0 | 2 | 1 | 0 | 1 | NL | NL | 13 |
| 27 | CPTC | III | T2N1aM0 | 2 | 2 | 0 | 1 | NL | NL | 1 |
| 28 | CPTC | III | T4N1bM0 | 2 | 2 | 0 | 0 | NL | NL | 2 |
| 29 | TCV PTC | III | T4N1bM0 | 3 | 3 | 0 | 0 | NL | NL | NA |
| 30 | CPTC | III | T2N1aM0 | NA | NA | NA | NA | NL | NL | NA |
| 31 | CPTC | III | T4N0M0 | 2 | 2 | 0 | 0 | NL | NL | NA |
| 32 | CPTC | III | T2N1aM0 | 3 | 3 | 0 | 0 | NL | NL | NA |
| 33 | CPTC | III | T2N1bM0 | 2 | 2 | 0 | 0 | NL | NL | 11 |
| 34 | ATC | IV | NA | 1 | 1 | 1 | 0 | NL | NL | NA |
| 35 | ATC | IV | NA | 1 | 1 | 1 | 0 | NL | NL | NA |
| 36 | ATC | IV | NA | 1 | 1 | 1 | 0 | NL | NL | NA |
| 37 | ATC | IV | NA | 2 | 2 | 1 | 0 | NL | MT | NA |

Table 3. (Supplementary material). Results of thyroid carcinomas examined for P53 mutational and immunohistochemical analysis and FAS mutational, immunohistochemical and RT-PCR analysis. CPTC: conventional papillary thyroid carcinoma, TCV PTC: tall cell variant papillary thyroid carcinoma, ATC: anaplastic thyroid carcinoma, NL: normal, MT: mutant, NA: non applicable. FAS immunoexpression; 0: positive cells ‹10%, 1: positive cells more than 10% and less than 40%, 2: positive cells more than 40% and less than 70%, 3: positive cells more than 70%. For P53 expression, score was either 0 for negative or 1 for positive expression. Numbers in s*Fas* column indicate the sample’s position in the agarose gel, in Figure 2.